1. Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study)
   Hiroshi Matsuoka et al, 2022, International Journal of Clinical Oncology CrossRef
2. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting
   Nieves Martínez-Lago et al, 2022, Scientific Reports CrossRef